Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 195

1.

Cancer. A bull's eye for targeted lung cancer therapy.

Minna JD, Gazdar AF, Sprang SR, Herz J.

Science. 2004 Jun 4;304(5676):1458-61. No abstract available.

PMID:
15178790
2.

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.

Paez JG, Jänne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, Naoki K, Sasaki H, Fujii Y, Eck MJ, Sellers WR, Johnson BE, Meyerson M.

Science. 2004 Jun 4;304(5676):1497-500. Epub 2004 Apr 29.

3.

Targeting targeted therapy.

Green MR.

N Engl J Med. 2004 May 20;350(21):2191-3. Epub 2004 Apr 29. No abstract available.

4.

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.

Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J, Haber DA.

N Engl J Med. 2004 May 20;350(21):2129-39. Epub 2004 Apr 29.

5.

[Mutations in the epidermal growth factor receptor and targeted therapy of non-small-cell lung cancer].

Lai RS, Xie L, Shen LS, He YM, Zhu CL.

Zhonghua Bing Li Xue Za Zhi. 2005 Nov;34(11):745-6. Chinese. No abstract available.

PMID:
16536324
6.

EGFR mutations and molecularly targeted therapy: a new era in the treatment of lung cancer.

Dowell JE, Minna JD.

Nat Clin Pract Oncol. 2006 Apr;3(4):170-1. No abstract available.

PMID:
16596125
7.
8.

Epidermal growth factor receptor mutations in non-small cell lung cancer: predicting clinical response to kinase inhibitors.

Sequist LV, Haber DA, Lynch TJ.

Clin Cancer Res. 2005 Aug 15;11(16):5668-70. No abstract available.

9.
10.

Unusual cases in multiple myeloma and a dramatic response in metastatic lung cancer: case 4. Mutation of the epidermal growth factor receptor in an elderly man with advanced, gefitinib-responsive, non-small-cell lung cancer.

Cho D, Kocher O, Lee JC, Tenen DG, Meyerson ML, Janne PA, Halmos B.

J Clin Oncol. 2005 Jan 1;23(1):235-7. No abstract available. Erratum in: J Clin Oncol. 2005 Apr 1;23(10):2444.

PMID:
15625379
11.
12.

Clairvoyance or reliable prediction of the future?

van Zandwijk N, van de Vijver MJ.

Ann Oncol. 2007 Mar;18(3):407-8. No abstract available.

PMID:
17322538
13.

[New era in cancer therapy. Gefitinib: small molecule--strong action].

Arnheim K.

MMW Fortschr Med. 2004 Nov 18;146(47):70-1. German. No abstract available.

PMID:
15624666
14.

Epidermal growth factor receptor mutations are associated with gefitinib sensitivity in non-small cell lung cancer in Japanese.

Uramoto H, Sugio K, Oyama T, Ono K, Sugaya M, Yoshimatsu T, Hanagiri T, Morita M, Yasumoto K.

Lung Cancer. 2006 Jan;51(1):71-7. Epub 2005 Sep 29.

PMID:
16198442
15.

Retreatment of gefitinib in patients with non-small-cell lung cancer who previously controlled to gefitinib: a single-arm, open-label, phase II study.

Oh IJ, Ban HJ, Kim KS, Kim YC.

Lung Cancer. 2012 Jul;77(1):121-7. doi: 10.1016/j.lungcan.2012.01.012. Epub 2012 Feb 12.

PMID:
22333554
16.

First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations.

Sequist LV, Martins RG, Spigel D, Grunberg SM, Spira A, Jänne PA, Joshi VA, McCollum D, Evans TL, Muzikansky A, Kuhlmann GL, Han M, Goldberg JS, Settleman J, Iafrate AJ, Engelman JA, Haber DA, Johnson BE, Lynch TJ.

J Clin Oncol. 2008 May 20;26(15):2442-9. doi: 10.1200/JCO.2007.14.8494. Epub 2008 May 5. Erratum in: J Clin Oncol. 2008 Jul 10;26(20):3472.

PMID:
18458038
17.

EGFR mutation conferring primary resistance to gefitinib in non-small-cell lung cancer.

Shih JY, Gow CH, Yang PC.

N Engl J Med. 2005 Jul 14;353(2):207-8. No abstract available.

18.

The role of third-generation epithelial growth factor receptor inhibitors in non-small cell lung cancer.

Sequist LV.

Clin Adv Hematol Oncol. 2015 Mar;13(3):147-9. No abstract available.

PMID:
26352419
19.

Gefitinib as first-line treatment in elderly epidermal growth factor receptor-mutated patients with advanced lung adenocarcinoma: results of a Nagano Lung Cancer Research Group study.

Asami K, Koizumi T, Hirai K, Ameshima S, Tsukadaira A, Morozumi N, Morikawa A, Atagi S, Kawahara M.

Clin Lung Cancer. 2011 Nov;12(6):387-92. doi: 10.1016/j.cllc.2011.02.004. Epub 2011 May 10.

PMID:
21729650
20.

Somatic mutations of the epidermal growth factor receptor and non-small-cell lung cancer.

Zhang X, Chang A.

J Med Genet. 2007 Mar;44(3):166-72. Epub 2006 Dec 8. Review.

Supplemental Content

Support Center